You are here
Home 🌿 Marijuana Business News 🌿 Aphria profits up on Liberty Health sale, while U.S. cannabis prospects improve 🌿Aphria profits up on Liberty Health sale, while U.S. cannabis prospects improve

Aphria revenues double, year-over-year, thanks to Broken Coast acquisition and new patients.
Aphria Inc.’s third-quarter income nearly tripled year-over-year, in a busy three months that saw the cannabis company begin to sell its U.S. assets and acquire smaller licensed producer Broken Coast Cannabis Inc.
On Monday, the Leamington, Ont.-based medical marijuana grower announced third quarter net income of $12.95 million or 8 cents a share, compared with $4.95 million or 4 cents a share the year before. The increase was due, in large part, to a $26.3 million gain realized on the sale of Liberty Health Science Inc. shares.
Aphria, which still owns 28 per cent of the U.S.-focused marijuana company, began selling its Liberty Health shares after the TMX Group Ltd. came out against TSX-listed cannabis companies operating in the U.S.
Quarterly profit also got a boost from growth in revenue, which doubled year-over-year, to $10.3 million from $5.1 million.
“This includes $1.1 million from Broken Coast during the month of February, the first month of our ownership,” Carl Merton, Aphria’s chief financial officer, said on a call with analysts. Aphria acquired the boutique B.C. grower in January for roughly $230 million, mostly in shares.
New medical patients also drove revenue growth, with Aphria selling around 270,000 gram equivalents (of dried bud and oil) to patients on-boarded in the third quarter.
Retail prices were up, with the average gram selling for $8.30 compared with $8.10 in the previous quarter (wholesale excluded). Meanwhile, “all-in cost of sales” declined to $1.56 a gram from $2.13 in the second quarter.
While the company sold 445 kilograms to other licensed producers in the three months leading up to Feb. 28, the quarter marked a turning point in Aphria’s strategy, chief executive Vic Neufeld said on the analyst call.
Aphria will no longer sell marijuana wholesale to other companies, in order to stockpile product ahead of recreational legalization, which is expected sometime in late summer or early fall.
“If we don’t have 8,000 to 10,000 kilos available for the rec market in the month of September, then we will not be able to service what we are projecting to be the conservative opening order from various provincial regulators,” Neufeld said.
Like other licensed producers, Aphria is racing to build new facilities or adapt existing greenhouses in expectation of recreational demand.
It recently completed a 200,000-square-foot greenhouse expansion, which Neufeld said would start producing in the coming weeks. A further million square feet of greenhouse space is under construction, although it won’t come online until January 2019.
“We can struggle from October through January,” Neufeld said.
Unlike other large companies, such as Canopy Growth Corp. or Aurora Cannabis Inc., Aphria hasn’t begun to generate revenue from cannabis exports.
It acquired Nuuvera Inc., which it has rebranded as Aphria International Inc., after the end of the third quarter, in an attempt to match its competitors’ international scope. It’s still waiting, however, on GMP certification for its facilities, which is a prerequisite for selling marijuana into Europe.
Recent developments in the U.S., however, may give Aphria at least one competitive edge internationally, thanks to its investment in Liberty Health.
On Friday, it was reported that U.S. President Donald Trump was considering protecting states that had already legalized marijuana from federal government intervention.
“We’re very excited,” said Neufeld. “This is just another advancement of getting to the position where medical cannabis in the U.S. moves to a Schedule II (drug).”
While Aphria has agreed sell off its stake in Liberty Health, this is happening in several stages due to Canadian Securities Exchange escrow rules. Aphria is expected to sell off another 15 per cent stake in Liberty Health in July.
“Will there be enough advancement between now and late July? Probably not,” Neufeld said. But if Trump does take a more accepting approach to marijuana, the TMX Group “will focus more eyeballs on what’s happening in the U.S.,” Neufeld said.
420 Intel is Your Source for Marijuana News
420 Intel Canada is your leading news source for the Canadian cannabis industry. Get the latest updates on Canadian cannabis stocks and developments on how Canada continues to be a major player in the worldwide recreational and medical cannabis industry.
420 Intel Canada is the Canadian Industry news outlet that will keep you updated on how these Canadian developments in recreational and medical marijuana will impact the country and the world. Our commitment is to bring you the most important cannabis news stories from across Canada every day of the week.
Marijuana industry news is a constant endeavor with new developments each day. For marijuana news across the True North, 420 Intel Canada promises to bring you quality, Canadian, cannabis industry news.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.